Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review

     Omeros Ophthalmology Product OMS302 Granted Eligibility for European
                              Centralized Review

-- Centralized Procedure Used for Products that Represent Therapeutic
Innovation --

PR Newswire

SEATTLE, April 30, 2013

SEATTLE, April 30, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER)
today announced that the European Medicines Agency (EMA) has confirmed that
the Company's planned Marketing Authorization Application (MAA) for its
ophthalmology product OMS302 can be submitted and reviewed under the EMA's
centralized procedure. OMS302, which contains mydriatic (pupil-dilating) and
anti-inflammatory agents, is the Company's product being developed for use
during intraocular lens replacement, including cataract surgery and refractive
lens exchange. EMA's Committee for Medicinal Products for Human Use granted
this eligibility for OMS302 because it represents a significant therapeutic
innovation.

The EMA's centralized procedure allows submission of a single MAA that, when
approved, authorizes the drug to be marketed in all European Union member
states and European Free Trade Association countries rather than requiring
separate national approvals. The centralized process can significantly
accelerate widespread commercialization in Europe. Omeros intends to submit a
New Drug Application for OMS302 to the U.S. Food and Drug Administration this
quarter and an MAA to European regulators in mid-2013.

"The determination that OMS302 qualifies for centralized filing underscores
the product's therapeutic innovation and allows Omeros to pursue more rapid
commercialization throughout Europe," stated Gregory A. Demopulos, M.D.,
chairman and chief executive officer of Omeros. "OMS302 promises significant
benefits to ophthalmic surgeons and their patients, and we look forward to
launching it in the U.S. and Europe next year."

About Omeros' OMS302 Program
OMS302 is Omeros' product being developed for use during intraocular lens
replacement (ILR), including cataract surgery and refractive lens exchange.
OMS302 is a proprietary combination of the mydriatic (pupil dilating) agent
phenylephrine and the anti-inflammatory agent ketorolac. Omeros recently
completed its successful OMS302 Phase 3 clinical program and expects to submit
a New Drug Application to the U.S. Food and Drug Administration this quarter
and a Marketing Authorization Application to the European Medicines Agency in
mid-2013.

ILR involves replacement of the original lens of the eye with an artificial
intraocular lens. These procedures are typically performed to replace a lens
opacified by a cataract or to correct a refractive error of the lens (i.e.,
refractive lens exchange). OMS302 is added to standard irrigation solution
used in ILR and delivered within the eye to maintain intraoperative mydriasis
(pupil dilation), to prevent surgically induced miosis (pupil constriction),
and to reduce postoperative pain and irritation. Maintenance of mydriasis is
critical to the safety and surgical ease of the procedure. Intraoperative
pupil constriction increases the risk of injury to intraocular structures and
can substantially prolong surgical time.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing products targeting inflammation, coagulopathies
and disorders of the central nervous system. The Company's most clinically
advanced product candidates, OMS302 for lens replacement surgery and OMS103HP
for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform
designed to improve clinical outcomes of patients undergoing a wide range of
surgical and medical procedures. Omeros has five clinical development
programs. Omeros may also have the near-term capability, through its GPCR
program, to add a large number of new drug targets and their corresponding
compounds to the market. Behind its clinical candidates and GPCR platform,
Omeros is building a diverse pipeline of protein and small-molecule
preclinical programs targeting inflammation, coagulopathies and central
nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the
Private Securities Litigation Reform Act of 1995, which are subject to the
"safe harbor" created by those sections. These statements include, but are not
limited to, Omeros' expectations that it will submit marketing applications
for OMS302 in 2013; that the centralized procedure will allow more rapid
commercialization of OMS302 in Europe, if approved; that Omeros will begin
selling OMS302 next year, if approved; and that Omeros may have capability,
through its GPCR program, to add a large number of new drug targets and their
corresponding compounds to the market. Forward-looking statements are based on
management's beliefs and assumptions and on information available to
management only as of the date of this press release. Omeros' actual results
could differ materially from those anticipated in these forward-looking
statements for many reasons, including, without limitation, the risks,
uncertainties and other factors described under the heading "Risk Factors" in
the Company's Annual Report on Form 10-K filed with the Securities and
Exchange Commission on March 18, 2013. Given these risks, uncertainties and
other factors, you should not place undue reliance on these forward-looking
statements, and the Company assumes no obligation to update these
forward-looking statements publicly, even if new information becomes available
in the future.

SOURCE Omeros Corporation

Contact: Jennifer Cook Williams, Cook Williams Communications, Inc., Investor
and Media Relations, +1-360-668-3701, jennifer@cwcomm.org
 
Press spacebar to pause and continue. Press esc to stop.